Hikma Pharmaceuticals Share Discussion Threads

[soniraman] 10/1/2018 08:43

Jeffries downgrades to underperform : 894

[mrthomas] 02/1/2018 15:34

Would buy This if it gets below 11as people have said strong balance sheet should make a profit reasonly good cash flow

[death by donut] 19/12/2017 20:28

Hikma reaches licensing agreement with Celltrion for third biosimilar product in the Middle East and North Africa

London, 19 December 2017 - Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable) announces that it has reached a licensing agreement with South Korea-based Celltrion, Inc. and Celltrion Healthcare, Inc (Celltrion) for the first biosimilar monoclonal Antibody (mAb) in oncology to be granted European marketing authorisation, Truxima(TM) (rituximab). Hikma now has exclusive agreements with Celltrion for three biosimilar products - Truxima(TM) (rituximab), Remsima(R) (infliximab) and Herzuma(R) (trastuzumab) - in all its MENA markets.

Truxima(TM) is mAb biosimilar to Roche's MabThera(R) (rituximab), which is used to treat patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis.

Under the terms of the agreement, Hikma has the exclusive rights to distribute and market Truxima(TM) (rituximab) in all of its MENA markets, leveraging Hikma's strong local presence, biosimilar expertise, sales and marketing capabilities and regulatory expertise.

Mazen Darwazah, Vice Chairman and CEO of MENA and Emerging Markets said, "We are pleased to be adding Truxima(TM) to our biosimilar and oncology portfolio, building on the success of our partnership with Celltrion in the MENA region. Global partnerships are an integral part of our strategy to enhance our portfolio in key therapeutic areas and increase patients' access to high-quality, affordable medicines."

[suetballs] 19/12/2017 16:26

Do I detect a pulse?
Suet

[r ball] 15/12/2017 05:59

Treva cutting 25% of workforce? I wonder what Indian firms are doing? Industry shake out?

[justiceforthemany] 13/12/2017 12:45

Another new product announced today to boost earnings and profits

[broadwood] 08/12/2017 16:27

Is this finally the start of the great fightback?

[hickool] 05/12/2017 09:12

Was a mistake to buy this at £13.50. Low debt and healthy b/sheet so will hold for a while.

[justiceforthemany] 04/12/2017 19:37

H2 tends to be far stronger than H1. share price drop way overdone IMO as H1 2017 was no worse than H1 2016. After another drop today worst case this is trading on a P/E of just 12. Great balance sheet also.

[r ball] 20/11/2017 17:35

If fda settlement was sorted I would expect share price of £25. The main issue is Indian access to us generics market.

[justiceforthemany] 20/11/2017 14:31

Check the reports pye. When the share price dropped to 9 the forward P/E was 10.

[bantam175] 20/11/2017 14:06

Well it took 9 months to get down here, how long to get back I wonder?

Settlement with FDA on the cards maybe? Given current rise.

Time will tell as always.

[pyemckay] 19/11/2017 18:43

justice- stop posting incorrect data. This is not on a pe of 10.

[suetballs] 16/11/2017 10:41

Gosh - could it be a blue day?
Suet

[justiceforthemany] 14/11/2017 15:29

Core earnings for this year are expected to be flat on 2016 at 118.5c/91p. A P/E of 10 is far too low for this sector and a company with a great balance sheet. Numis target of 1300p seems fair. Peel Hunt going for 1390p. Current share price of 950p is ridiculous and shorter driven.
HIK Peel Hunt Hold 949.50 960.50 - *1,390.00 Target Price*

[citytrader66] 14/11/2017 08:30

got some at 913.2p. had quote for lower but didn't take it then couldn't buy for a minute. always the same at the bottom.

[its the oxman] 13/11/2017 16:04

Keep waiting for this to trend sideways before considering a purchase, but it keeps falling. 900p not all that far away.

[karateboy] 09/11/2017 20:55

Surprised to see that they still have a major disagreement with FDA. It will be great if they can resolve the issue in Q1 2018 .

[bantam175] 09/11/2017 14:05

Could have been a shorters last hurrah before the big boys pile back in.

The FDA problems started this slide. If it gets sorted out the upside should be excellent.

Time will tell as always....

[chc15] 09/11/2017 09:24

awful stuff, I do not understand why institutions were buying so heavily recently - they are losing millions - they haven't got a clue. maybe a bounce in coming days?

[nortic 007] 09/11/2017 09:10

Buy note out from Numis this morning £13

[bantam175] 09/11/2017 08:42

Hard to believe there was a broker forecast of £35 earlier this year.

[essentialinvestor] 09/11/2017 08:36

PER still looks generous imv, however there may be more sector
consolidation at some point imv.

[broadwood] 09/11/2017 08:15

Bant - agree.

Hikma Pharmaceuticals has revised its full year expectations for its generics business but continues to expect full year revenue to be around $2.0bn in constant currency.

The group said its injectables and branded businesses were delivering a good performance but like many of its competitors, it was experiencing challenging conditions in the US generics market.